International Stem Cell (ISCO) Total Current Liabilities (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Total Current Liabilities of $4.6 million for Q4 2025, down 2.33% year-over-year from $4.7 million in Q4 2024, and down 1.63% quarter-over-quarter from $4.7 million in Q3 2025.
International Stem Cell (ISCO) Total Current Liabilities (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Total Current Liabilities for 16 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities fell 2.33% year-over-year to $4.6 million; the TTM figure through Dec 2025 stood at $4.6 million (down 2.33% YoY), while the FY2025 annual figure was $4.6 million, down 2.33% from the prior year.
- Total Current Liabilities slipped to $4.6 million in Q4 2025 per ISCO's latest filing, from $4.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $5.1 million in Q1 2025 and bottomed at $4.3 million in Q4 2021.
- Historically, Total Current Liabilities has averaged $4.7 million across 5 years, with a median of $4.7 million in 2022.
- Annual changes were most pronounced in 2021 — Total Current Liabilities surged 188.87% — and 2024, when it fell 2.98%.
- International Stem Cell's Total Current Liabilities stood at $4.3 million in 2021, then advanced by 8.19% to $4.6 million in 2022, then increased by 4.25% to $4.8 million in 2023, then dropped by 2.98% to $4.7 million in 2024, then decreased by 2.33% to $4.6 million in 2025.
- Business Quant data shows ISCO's Total Current Liabilities at $4.6 million in Q4 2025, $4.7 million in Q3 2025, and $4.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 4.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.98 Mn |
| Dec 31, 2025 | 4.58 Mn |
| Sep 30, 2025 | 4.66 Mn |
| Jun 30, 2025 | 4.94 Mn |
| Mar 31, 2025 | 5.11 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 4.72 Mn |
| Jun 30, 2024 | 5.02 Mn |
| Mar 31, 2024 | 4.97 Mn |
| Dec 31, 2023 | 4.83 Mn |
| Sep 30, 2023 | 4.68 Mn |
| Jun 30, 2023 | 4.74 Mn |
| Mar 31, 2023 | 4.83 Mn |
| Dec 31, 2022 | 4.64 Mn |
| Sep 30, 2022 | 4.61 Mn |
| Jun 30, 2022 | 4.69 Mn |
| Mar 31, 2022 | 4.81 Mn |
| Dec 31, 2021 | 4.28 Mn |
| Sep 30, 2021 | 4.35 Mn |
| Jun 30, 2021 | 4.43 Mn |